about
Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity.Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination.Immune-related Adverse Events of Dendritic Cell Vaccination Correlate With Immunologic and Clinical Outcome in Stage III and IV Melanoma Patients.Adjuvant dendritic cell vaccination induces tumor-specific immune responses in the majority of stage III melanoma patients.Ipilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination.Dendritic Cell-Based Immunotherapy: State of the Art and Beyond.T-cell Landscape in a Primary Melanoma Predicts the Survival of Patients with Metastatic Disease after Their Treatment with Dendritic Cell Vaccines.Naturally circulating dendritic cells to vaccinate cancer patients.Direct inhibition of STAT signaling by platinum drugs contributes to their anti-cancer activity.Intranodal vaccination with mRNA-optimized dendritic cells in metastatic melanoma patientsImportance of helper T-cell activation in dendritic cell-based anticancer immunotherapy.Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors.Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination.Prognostic significance and mechanism of Treg infiltration in human brain tumors.Adjuvant Dendritic Cell Vaccination in High-Risk Uveal Melanoma.Vaccination with mRNA-Electroporated Dendritic Cells Induces Robust Tumor Antigen-Specific CD4+ and CD8+ T Cells Responses in Stage III and IV Melanoma PatientsDendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right TimeLong Overall Survival After Dendritic Cell Vaccination in Metastatic Uveal Melanoma PatientsSkin-Test Infiltrating Lymphocytes Early Predict Clinical Outcome of Dendritic Cell-Based Vaccination in Metastatic MelanomaHealth-related quality of life analysis in stage III melanoma patients treated with adjuvant dendritic cell therapyThe clinical application of cancer immunotherapy based on naturally circulating dendritic cellsEffective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic CellsReal-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal MelanomaEarly Recurrence in Completely Resected IIIB and IIIC Melanoma Warrants Restaging Prior to Adjuvant TherapyAutologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trialHuman pDCs Are Superior to cDC2s in Attracting Cytolytic Lymphocytes in Melanoma Patients Receiving DC Vaccination
P50
Q27323878-FCA4A381-C19A-49D5-A6B6-7AF20B39F017Q36597517-97847C47-1486-4328-BE2A-04378205C2C7Q36992766-974E1F64-6327-48B7-ADDB-EE79E65C7C1CQ37222157-12F3273C-E840-4CC2-8607-A4A1B3A4734EQ37224609-2539EE54-490D-4128-8D51-E4DFA763F292Q38809786-27DEDD77-EE86-435F-9C82-3BD18DC52E4AQ40745798-93FE31D0-1937-4051-92C8-566DE5FE48BBQ40930007-A17E61F2-AABF-4611-B713-FD98F615EA2CQ41551997-ABCEC617-9263-4633-B6B4-EEB8AD583D05Q41967129-1846EC48-C463-4304-86FE-69F5014C79FBQ42238407-F6E4D2BF-1811-4031-822B-BF5501C1F241Q42554303-29478BFF-6E89-4154-AB13-F9341E995E2CQ46885041-82A317D6-727B-4736-9E7C-D1D851D613F8Q48170914-0E93737B-D9AB-4103-BF1C-A0174FCB5257Q53058929-0C26A0C8-7E85-4E2A-8C44-F8CC7D4E59B4Q56637518-2B2BA201-1427-42F6-B205-152918A495BEQ57486475-8F6597E4-32BE-4642-A54A-C0B4E1F2BE16Q58619847-6E30F36C-69F6-43C7-B68C-5BF58AC9DC7EQ58619897-5DDCD406-DD24-4C98-B551-848ED9B9B5E8Q64030269-2BE82271-FCCB-4F90-9834-4137310DC3C7Q64103056-5FAFAD26-DE35-4941-B76B-3C605463B3C8Q64166970-4E97C93D-A971-4D4E-8A5B-A4FC6A8731ECQ90775726-E317E92F-0ACF-4056-8E8E-0BABBCDFE96CQ92106711-164CC284-022D-4130-BBF1-CB14CCBA73F9Q92933884-935BFA33-B384-431E-829A-1D8A3059C944Q93032898-7FD0F63D-81F7-4A2B-8116-963C20E3361E
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Kalijn Bol
@ast
Kalijn Bol
@en
Kalijn Bol
@es
Kalijn Bol
@nl
Kalijn Bol
@sl
type
label
Kalijn Bol
@ast
Kalijn Bol
@en
Kalijn Bol
@es
Kalijn Bol
@nl
Kalijn Bol
@sl
prefLabel
Kalijn Bol
@ast
Kalijn Bol
@en
Kalijn Bol
@es
Kalijn Bol
@nl
Kalijn Bol
@sl
P1006
P214
P1006
P1053
F-4595-2014
P106
P214
P31
P3829
P496
0000-0003-4165-2040
P7859
viaf-317189238